Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Reports Stock Sales
SEC Form 4 Filing
Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported multiple sales of common stock between March 19 and March 21, 2024, according to a recent SEC Form 4 filing.
Summary
- Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports sales of ARS Pharmaceuticals' common stock on March 19 and March 21, 2024.
- On March 19, 2024, 976 shares were sold at a weighted average price of $9.0273, with prices ranging from $9.01 to $9.09.
- Also on March 19, 2024, 942 shares were sold at a weighted average price of $9.0376, with prices ranging from $9.02 to $9.08.
- On March 21, 2024, 372 shares were sold at $9.
- Also on March 21, 2024, 100 shares were sold at $9.
- The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
- Tanimoto also holds shares indirectly through several trusts, including the Sarina Tanimoto Charitable Remainder UniTrust and the Lowenthal-Tanimoto Family Trust.
- Her spouse also holds shares in trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a report of stock sales under a pre-existing plan, not necessarily indicative of positive or negative sentiment towards the company.
Industry Context
This filing is a routine disclosure of insider stock sales. It's common for executives to have pre-arranged trading plans to sell shares over time.
Key Dates
| Date | Description |
|---|---|
| January 7, 2020 | Date of Sarina Tanimoto Charitable Remainder UniTrust |
| April 3, 2006 | Date of Lowenthal-Tanimoto Family Trust |
| March 31, 2023 | Date of Rule 10b5-1 trading plan |
| March 19, 2024 | Date of stock sales |
| March 21, 2024 | Date of stock sales |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.